No explanation in the Half Year Report as to why Starpharma have
failed to achieve any of 0-9 month key and critical targets they set for themselves and gave shareholders hope for. Furthermore, no revised target timelines was given. Poor.
I also couldn’t care less that CM can ‘vouch for the hard work and dedication of everyone at Starpharma’. I would expect nothing less, wouldn’t you? But where’s the results? Where’s the deals? Show me the money!
Also very
importantly for everyone that didn’t pick it up, back in the May 2024 business update, (less than one year ago) the CEO stated this about radiodiagnostics:
’Starpharma will prioritise the development of its DEP-HER2 radiodiagnostic program towards a first-in-human clinical study to initiate
within the next
12 months.’
Well that
should’ve meant a Phase One trial would start by May
this year.
But the language changed at at the 2024 AGM and became: ‘We aim to be in Phase One in 2025’
Now the language is: to ensure the trial can start as efficiently as possible ….
Yeah ok, I hope to be proved wrong but I have zero confidence
any of the Radiopharmaceutical programs will commence Phase One in 2025.
(20min delay)